EP2477594A4 - Isoketal scavengers and mitigation of disorders involving oxidative injury - Google Patents

Isoketal scavengers and mitigation of disorders involving oxidative injury

Info

Publication number
EP2477594A4
EP2477594A4 EP09847430A EP09847430A EP2477594A4 EP 2477594 A4 EP2477594 A4 EP 2477594A4 EP 09847430 A EP09847430 A EP 09847430A EP 09847430 A EP09847430 A EP 09847430A EP 2477594 A4 EP2477594 A4 EP 2477594A4
Authority
EP
European Patent Office
Prior art keywords
isoketal
scavengers
mitigation
disorders involving
oxidative injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09847430A
Other languages
German (de)
French (fr)
Other versions
EP2477594A1 (en
Inventor
Jackson L Roberts
Jeffrey R Balser
Sean S Davies
Venkataraman Amarnath
Prakash Viswanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP2477594A1 publication Critical patent/EP2477594A1/en
Publication of EP2477594A4 publication Critical patent/EP2477594A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09847430A 2009-07-15 2009-07-15 Isoketal scavengers and mitigation of disorders involving oxidative injury Withdrawn EP2477594A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/050644 WO2011008202A1 (en) 2009-07-15 2009-07-15 Isoketal scavengers and mitigation of disorders involving oxidative injury

Publications (2)

Publication Number Publication Date
EP2477594A1 EP2477594A1 (en) 2012-07-25
EP2477594A4 true EP2477594A4 (en) 2013-03-13

Family

ID=43449619

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09847430A Withdrawn EP2477594A4 (en) 2009-07-15 2009-07-15 Isoketal scavengers and mitigation of disorders involving oxidative injury

Country Status (2)

Country Link
EP (1) EP2477594A4 (en)
WO (1) WO2011008202A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JP6280033B2 (en) * 2011-07-12 2018-02-14 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ Method of treating inflammation and hypertension with a gamma-ketoaldehyde scavenger
US9604997B2 (en) 2012-12-20 2017-03-28 Aldeyra Therapeutics, Inc. Peri-carbinols
KR102243169B1 (en) 2013-01-23 2021-04-22 알데이라 테라퓨틱스, 아이엔씨. Toxic aldehyde related diseases and treatment
CA2898869A1 (en) 2013-01-25 2014-07-31 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
CA2996183A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
AU2017293950B2 (en) * 2016-07-07 2023-06-15 Vanderbilt University Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
ES2968462T3 (en) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Polymorphic salt of 6-chloro-3-amino-2(2-hydroxyprolyl) quinoline and uses thereof
BR112019022523A2 (en) * 2017-04-27 2020-05-12 Vanderbilt University METHODS FOR TREATING AEROSCLEROSIS WITH GETO-KETOALDEHYDE SEQUESTRANTS
MX2020003425A (en) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Treatment of inflammatory disorders.
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115869258A (en) 2018-09-25 2023-03-31 奥尔德拉医疗公司 Formulation for treating dry eye
JP2022526917A (en) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド Ophthalmic preparations and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20080227776A1 (en) * 2005-06-15 2008-09-18 Oates John A Inhibitors of hemeprotein-catalyzed lipid peroxidation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277826B1 (en) * 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20080227776A1 (en) * 2005-06-15 2008-09-18 Oates John A Inhibitors of hemeprotein-catalyzed lipid peroxidation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERNOUD-HUBAC N ET AL: "Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation", BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OF LIPIDS, ELSEVIER, AMSTERDAM, NL, vol. 1791, no. 4, 1 April 2009 (2009-04-01), pages 307 - 313, XP026011351, ISSN: 1388-1981, [retrieved on 20090221], DOI: 10.1016/J.BBALIP.2009.02.003 *
BOYDEN PENELOPE A ET AL: "Potential role of isoketals formed via the isoprostane pathway of lipid peroxidation in ischemic arrhythmias.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY NOV 2007, vol. 50, no. 5, November 2007 (2007-11-01), pages 480 - 486, XP002691144, ISSN: 0160-2446 *
CIRCULATORY SHOCK 1981, vol. 8, no. 3, 1981, pages 273 - 282, ISSN: 0092-6213 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, MAEZAWA H ET AL: "THE EFFECT OF ONO-3144 ON LIMITING INFARCT SIZE IN A RAT MODEL OF MYOCARDIAL INFARCTION AND REPERFUSION", XP002691142, Database accession no. PREV199192008141 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1981, LEFER A M ET AL: "Beneficial actions of a free radical scavenger in traumatic shock and myocardial ischemia.", XP002691143, Database accession no. NLM7249259 *
DAVIES SEAN S ET AL: "Treatment With Isoketal Scavenger, Salicylamine, Prevents Loss of Working Memory in Humanized Apoe4 Mice", FREE RADICAL BIOLOGY & MEDICINE, vol. 45, no. Suppl. 1, 2008, & 15TH ANNUAL MEETING OF THE SOCIETY-FOR-FREE-RADICAL-BIOLOGY-AND-MEDICINE; INDIANAPOLIS, IN, USA; NOVEMBER 19 -23, 2008, pages S103 - S104, XP002691141, ISSN: 0891-5849 *
DOKKYO JOURNAL OF MEDICAL SCIENCES, vol. 17, no. 2, 1990, pages 85 - 92, ISSN: 0385-5023 *
NEGRE-SALVAYRE A ET AL: "Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.", BRITISH JOURNAL OF PHARMACOLOGY JAN 2008, vol. 153, no. 1, January 2008 (2008-01-01), pages 6 - 20, XP002691145, ISSN: 0007-1188 *
See also references of WO2011008202A1 *

Also Published As

Publication number Publication date
WO2011008202A1 (en) 2011-01-20
EP2477594A1 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
EP2477594A4 (en) Isoketal scavengers and mitigation of disorders involving oxidative injury
HRP20190521T1 (en) Novel compositions for preventing and/or treating lysosomal storage disorders
EP2542147A4 (en) Devices and methods for treating psychological disorders
EP2461819A4 (en) Methods and compositions for treating trinucleotide repeat disorders
ZA201105287B (en) Prevention and treatment of rotavirus diarrhoea
HK1166305A1 (en) Compositions and methods for the treatment of inflammation
EP2498798A4 (en) Compositions and methods for wound treatment
EP2509596A4 (en) Compounds and methods of treating ocular disorders
IL215583A0 (en) Methods for preventing and/or treating lysosomal storage disorders
EP2550361A4 (en) Compositions and methods for treating neurological disorders
EP2753363A4 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
HK1252916A1 (en) Methods for treatment of nephrotic syndrome and related conditions
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
EP2491389A4 (en) Detection and treatment of lrp4-associated neurotransmission disorders
IL215990A0 (en) Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders
IL221809A (en) Herbal composition for preventing and/or treating anxiety and related conditions
EP2544683A4 (en) Synergistic effect of tocotrienols and curcumin
ZA201304381B (en) Novel-19-nor-steroid and their use for treating progesterone-dependent conditions
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
EP2501672A4 (en) Compositions and methods for treating hyperproliferative disorders
GB201003124D0 (en) Treatment of oxidative stress disorders
GB0906175D0 (en) Treatment of lysosomal storage disorders
GB0908661D0 (en) Treatment of lysosomal storage disorders
TWM372102U (en) Skin-caring and treating device
GB201020304D0 (en) Treatment and prevention of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20130130BHEP

Ipc: A61K 31/198 20060101ALI20130130BHEP

Ipc: A61K 8/02 20060101AFI20130130BHEP

Ipc: A61P 9/10 20060101ALI20130130BHEP

Ipc: A61K 31/137 20060101ALI20130130BHEP

Ipc: A61P 9/00 20060101ALI20130130BHEP

Ipc: A61P 25/28 20060101ALI20130130BHEP

Ipc: A61P 39/06 20060101ALI20130130BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130912